Citadel Advisors
AUTL

Citadel Advisors’s Autolus Therapeutics AUTL Stock Holding History

Citadel Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25,300
Closed -$41.2K – 12633
2025
Q3 		$41.2K Sell
25,300
-3,400
-12% -$6.64K ﹤0.01% 12282
2025
Q2 		$65.4K Sell
28,700
-47,200
-62% -$78K ﹤0.01% 11631
2025
Q1 		$118K Buy
75,900
+48,700
+179% +$98.9K ﹤0.01% 11237
2024
Q4 		$63.9K Buy
27,200
+26,400
+3,300% +$89.2K ﹤0.01% 12107
2024
Q3 		$2.9K Sell
800
-2,100
-72% -$8.38K ﹤0.01% 13710
2024
Q2 		$10.1K Sell
2,900
-4,700
-62% -$20.3K ﹤0.01% 13108
2024
Q1 		$48.5K Buy
7,600
+4,300
+130% +$26.8K ﹤0.01% 12200
2023
Q4 		$21.3K Buy
+3,300
New +$12.6K ﹤0.01% 12572
2023
Q3 		– Sell
-7,000
Closed -$16.7K – 14260
2023
Q2 		$16.7K Sell
7,000
-300
-4% -$712 ﹤0.01% 12887
2023
Q1 		$13.4K Buy
7,300
+5,700
+356% +$11.1K ﹤0.01% 13365
2022
Q4 		$3.04K Buy
+1,600
New +$4.05K ﹤0.01% 14259
2022
Q1 		– Sell
-21,400
Closed -$111K – 13548
2021
Q4 		$111K Sell
21,400
-23,300
-52% -$140K ﹤0.01% 12612
2021
Q3 		$293K Buy
+44,700
New +$282K ﹤0.01% 11101

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors's AUTL Position: Q2 2026 in Review

Citadel Advisors increased its Autolus Therapeutics (AUTL) stake by 51% in Q2 2026, buying an estimated $371K and bringing the position to 695,890 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #7945.

Citadel Advisors first reported a position in AUTL in Q2 2019 and has held it in 27 quarters since. The position peaked at $18.3M in Q2 2021. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Citadel Advisors held 695,890 shares of Autolus Therapeutics worth $1.11M as of Q2 2026.
  • Citadel Advisors bought 236,486 Autolus Therapeutics shares in Q2 2026, an estimated $371K.
  • Autolus Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #7945 holding.
  • Citadel Advisors first reported a position in Autolus Therapeutics in Q2 2019 and has held it in 27 quarters since.
  • Citadel Advisors's Autolus Therapeutics position peaked at $18.3M in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.